SCHEMBL2067384

SCHEMBL2067384

COCC(=O)Nc1ccc([N+](=O)[O-])c(C)n1

nearest known ligand 0.48

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 8/20 0.48
NPC1 O15118 6/20 0.48
SMN1; SMN2 Q16637 4/20 0.48
NFKB1 P19838 1/20 0.48
NFKB2 Q00653 1/20 0.48
RELA Q04206 1/20 0.48
HTT P42858 1/20 0.46
MAPT P10636 2/20 0.46
MEN1 O00255 4/20 0.45
KMT2A Q03164 4/20 0.45
POLB P06746 2/20 0.45
PKM P14618 2/20 0.44
ALDH1A1 P00352 3/20 0.43
LMNA P02545 1/20 0.43
TP53 P04637 1/20 0.41
MAPK1 P28482 1/20 0.41
CTDSP1 Q9GZU7 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21436871 0.82 RAB9A (0.57) RAB9ANPC1SMN1; SMN2NFKB1NFKB2
SCHEMBL2018202 0.80 CYP1A2 (0.53) SMN1; SMN2HTTMAPTMEN1KMT2A
SCHEMBL15228257 0.77 RAB9A (0.59) RAB9ANPC1SMN1; SMN2MAPTMEN1
SCHEMBL2068391 0.77 RAB9A (0.43) RAB9ANPC1SMN1; SMN2HTTMAPT
SCHEMBL14266751 0.77 MAPT (0.43) RAB9ANPC1SMN1; SMN2NFKB1NFKB2
SCHEMBL30051515 0.76 POLB (0.40) RAB9ANPC1SMN1; SMN2MAPTMEN1
SCHEMBL27987224 0.75 MEN1 (0.47) RAB9ANPC1SMN1; SMN2NFKB1NFKB2
SCHEMBL4515030 0.75 MEN1 (0.38) RAB9ANPC1SMN1; SMN2NFKB1NFKB2
SCHEMBL4515027 0.75 MEN1 (0.38) RAB9ANPC1SMN1; SMN2NFKB1NFKB2
SCHEMBL4515018 0.75 MEN1 (0.38) RAB9ANPC1SMN1; SMN2NFKB1NFKB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2438063-A1 1H-IMIDAZO[4,5-C]QUINOLINONE COMPOUNDS, USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES Novartis AG (CH) 2012-04-11 EP disclosed
WO-2010139747-A1 1H-IMIDAZO[4, 5-c]QUINOLINONE COMPOUNDS, USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES NOVARTIS AG (CH) 2010-12-09 WO disclosed
US-20100311714-A1 1H-IMIDAZO[4,5-c]QUINOLINONE COMPOUNDS NOVARTIS AG (CH) 2010-12-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100311714-A1 1H-IMIDAZO[4,5-c]QUINOLINONE COMPOUNDS PRKCA, ABL1, MYLK2 RAB9A 646/4885NPC1 388/4885SMN1; SMN2 1734/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.